Calcutta, India

Chiranjib Pal


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Chiranjib Pal

Introduction

Chiranjib Pal is a notable inventor based in Calcutta, India. He has made significant contributions to the field of immunotherapy through his innovative research and development. His work focuses on enhancing graft survival and combating diseases through advanced cellular techniques.

Latest Patents

Chiranjib Pal holds a patent for an "In vitro method to generate dendritic Langerhans type cells." This patent describes a method for developing dendritic Langerhans type cells, which are crucial for immunotherapy against cancer and infectious diseases. The method involves culturing cells from peripheral blood monocytes and bone marrow in a medium containing platelets from the same or closely related species. The culture is then incubated at temperatures between 30 to 40°C for a sufficient period to allow the formation of mature dendritic Langerhans type cells. This innovative approach has the potential to significantly impact medical treatments.

Career Highlights

Chiranjib Pal is associated with the Council of Scientific and Industrial Research, where he continues to advance his research in immunotherapy and cellular biology. His dedication to scientific inquiry and innovation has positioned him as a key figure in his field.

Collaborations

Chiranjib has collaborated with esteemed colleagues such as Santu Bandyopadhyay and Keshab Chandra Roy. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Chiranjib Pal's contributions to the field of immunotherapy through his innovative patent and collaborative efforts highlight his importance as an inventor. His work not only advances scientific knowledge but also holds promise for future medical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…